MECOM and cancer: Our analysis identified numerous SIR-associated mutations in oncogenes (e.g., MECOM, NFATC2) and tumor suppressor genes (e.g., LRP1B, PTPRD), as well as in cancer-associated lncRNAs (e.g., MALAT1, NEAT1).